has submitted an amendment to the National Defense Authorization Act for Fiscal Year 2027 (NDAA) to provide $5 million in federal funding for alpha-gal syndrome research
Provide $5 million in dedicated federal funding for alpha-gal syndrome research through the FY2027 National Defense Authorization Act.
Occurrences
Evidence
legacy_unverified · Source version not recorded · locator unknown
The House Armed Services Committee floor amendment tracker lists floor amendment 104 / Rules amendment 0867 by Cleaver (MO), with Van Drew (NJ), stating it increases Combat and Operational Medicine Program R&D research by $5 million for alpha-gal syndrome research, offset by a $5 million reduction to advanced development; outcome: EB 1 Agreed to by Voice Vote.
legacy_unverified · Source version not recorded · locator unknown
The House Clerk records Roll Call Number 278 on July 22, 2026 for H.R. 8800, National Defense Authorization Act for Fiscal Year 2027; vote question: On Passage; status: Passed; yeas 216, nays 212, not voting 3.
Assessments
Cleaver materially advanced the promised $5 million alpha-gal syndrome research funding by offering the relevant FY2027 NDAA amendment, which was agreed to by voice vote and included before House passage of H.R. 8800 on July 22, 2026. However, the evidence shows only House-side adoption and passage, not final NDAA enactment or funds being appropriated or obligated, so the promised funding has not yet been fully delivered.